الفهرس 
Cytokine receptor like factor 2 (CRLF2) gene rearrangement in acute lymphoid leukemia (ALL) philadelphia
Abstract EnglishOnly 14 pages are availabe for public view
 |  | from | 90 |  |  |
| | | from | 90 | | |
Abstract
Background: Philadelphia chromosome like acute lymphoblastic leukemia (Ph-like ALL) is characterized by a gene expression profile similar to that of Breakpoint cluster region -v-abl Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) positive ALL and a poorer outcome. Rearrangements of cytokine receptor ligand factor 2 (CRLF2) are identified in approximately 50% of Ph-like and 10% of B Precursor ALL (B-ALL) patients and represents an unknown oncogenic mechanism in this subset of ALL patients.Objective: To identify the incidence of CRLF2 rearrangement in a cohort of B-ALL adult Egyptian patients who were treated with conventional ALL therapy and to assess its impact on progression free survival (PFS) and over survival (OS) at the National Cancer Institute, Cairo between 2017 to 2019.Patients and Methods: ALL diagnostic work-up was done according to the latest WHO 2016 edition and included Bone marrow (BM) aspiration, immunophenotyping,karyotyping, fluorescent in situ hybridization (FISH) for CRLF2 rearrangements with purinergic receptor P2Y, G-protein coupled, 8 or Immunoglobulin heavy Chain (IGH- CRLF2 or P2RY8-CRLF2).Results: Fifty-Four de novo patients with precursor B-ALL who presented to the National Cancer Institute from 2017 to 2019 (35 males, 19 females). 18.5% of B-ALL Patients recorded CRLF2 rearrangement their median age at diagnosis was 21.5 years (range 18 -59). Median Total leucocytes count (TLC) was 3.35X109/L. Median platelets count was 50.5X109/L (range 24-217). Median Bone Marrow (BM) blasts count was 90%. Median Peripheral Blood (PB) blasts count 77.5%.The progression free survival (PFS) percent in CRLF2 rearrangement patients was 10% and the overall survival (OS) percent was 60 %